Closing the Schistosomiasis Treatment Gap

After 12 years of global collaboration, we're proud to share the story behind a breakthrough that will change lives. Together, researchers and innovators from the Pediatric Praziquantel Consortium made it possible: a new treatment option specifically designed for preschool-aged children affected by schistosomiasis, a parasitic worm infection. This milestone marks a critical step in closing the treatment gap for young children and advancing efforts to eliminate schistosomiasis as a public health problem. 

Our partners across Japan, Germany, the Netherlands, Switzerland, the UK, Brazil, and African countries share what this collaborative R&D journey meant to them – showing what's possible when we work together toward the 2030 elimination goals.

Watch the video